Note: This data visualization was originally published in July 2019. This title of the piece was updated for clarity on April 15, 2020.
This page does not work on Internet Explorer 10 or below. Please use another browser.
The Pew Charitable Trusts has tracked the pipeline of antibiotics in clinical development since 2014 and has aggregated updates into an interactive tool that illustrates trends in the pipeline—as drugs are either approved, discontinued from development, or remain stagnant. This longitudinal assessment underscores the long-standing concerns of scientists, doctors, public health officials, and other stakeholders regarding the dangerously low number of antibiotics in development to address current and future patient needs, particularly for treating the most urgent bacterial threats, such as Gram-negative pathogens, and those prioritized by the Centers for Disease Control and Prevention and the World Health Organization .
Click the play button to see the evolution of the antibiotic pipeline since 2014, or click on an individual year to see the status of the pipeline at a particular point in time. (To view without animation, uncheck the “animate change” box.) To see additional information about each drug, hover over or tap any of the rectangles.
Visually impaired users may wish to skip to the summary of the content .
Antibiotics in Development Since 2014
Antibiotic
Expected to treat CDC urgent pathogen
Novel antibiotics
Expected to treat Gram-negative ESKAPE pathogens
Total approved antibiotics since 2014 : 4
Total discontinued antibiotics since 2014 : 6
2014
Phase 1
Active
Afabicin (Debio 1450) (Debiopharm International SA)
BAL30072 (Basilea Pharmaceutica Ltd.)
CRS3123 (Crestone Inc.)
Delpazolid (LCB01-0371) (LegoChem Biosciences Inc. (Shanghai HaiHe Pharmaceutical Co., Ltd./ CSPC Pharmaceutical Group Ltd. licensees))
Meropenem + nacubactam (OP0595/ RG6080) (Meiji Seika Pharma Co. Ltd./ Fedora Pharmaceuticals Inc.)
Contezolid (MRX-I) & contezolid acefosamil (MRX-4) (MicuRx Pharmaceuticals Inc.)
TD-1607 (Theravance Biopharma Inc.)
WCK 771/ WCK 2349 (levonadifloxacin, alalevonadifloxacin) (Wockhardt Ltd.)
Inactive
ACHN-975 (Achaogen Inc.)
EDP-788 (Enanta Pharmaceuticals Inc.)
Phase 2
Active
Avarofloxacin (Allergan PLC (formerly Actavis PLC))
Brilacidin (Innovation Pharmaceuticals Inc.)
Fetroja (cefiderocol) (Shionogi & Co. Ltd.)
Ceftaroline + avibactam (AstraZeneca PLC/ Forest Laboratories Inc.)
CG-549 (CrystalGenomics Inc.)
Finafloxacin (MerLion Pharmaceuticals GmbH)
Gepotidacin (GSK2140944) (GlaxoSmithKline PLC)
Recarbrio (imipenem/ cilastatin + relebactam) (Merck & Co. Inc.)
Xenleta (lefamulin) (Nabriva Therapeutics PLC)
Murepavadin (POL7080) (Polyphor AG)
Taigexyn (nemonoxacin) (TaiGen Biotechnology Co. Ltd.)
Nuzyra (omadacycline) (Paratek Pharmaceuticals Inc.)
Radezolid (Melinta Therapeutics Inc.)
Ramoplanin (Nanotherapeutics Inc.)
Ridinilazole (Summit Therapeutics PLC)
Zabofloxacin (Dong Wha Pharmaceutical Co. Ltd.)
Zoliflodacin (ETX0914) (Entasis Therapeutics Inc.)
Inactive
Cefilavacin (R-Pharm)
GSK-1322322 (GlaxoSmithKline PLC)
LFF571 (Novartis AG)
Phase 3
Active
Baxdela (delafloxacin) (Melinta Therapeutics Inc.)
Cadazolid (Actelion Pharmaceuticals Ltd.)
Xerava (eravacycline) (Tetraphase Pharmaceuticals Inc.)
Zemdri (plazomicin) (Achaogen Inc.)
T-4288 (solithromycin) (Toyama Chemical Co. Ltd.)
Surotomycin (Merck & Co. Inc. (formerly Cubist Pharmaceuticals Inc.))
ARV-1801 (fusidic acid) (Arrevus Inc.)
Vabomere (meropenem + vaborbactam) (The Medicines Company)
Inactive
Ceftobiprole (Basilea Pharmaceutica Ltd.)
New drug application
Active
Avycaz (ceftazidime + avibactam) (AstraZeneca PLC/ Actavis PLC)
Inactive
Approved
Active
Dalvance (dalbavancin) (Durata Therapeutics Inc.)
Orbactiv (oritavancin) (The Medicines Company)
Sivextro (tedizolid) (Cubist Pharmaceuticals Inc.)
Zerbaxa (ceftolozane + tazobactam) (Cubist Pharmaceuticals Inc.)
Inactive
2015
Phase 1
Active
BAL30072 (Basilea Pharmaceutica Ltd.)
CRS3123 (Crestone Inc.)
Delpazolid (LCB01-0371) (LegoChem Biosciences Inc. (Shanghai HaiHe Pharmaceutical Co., Ltd./ CSPC Pharmaceutical Group Ltd. licensees))
Meropenem + nacubactam (OP0595/ RG6080) (Meiji Seika Pharma Co. Ltd./ Fedora Pharmaceuticals Inc.)
MGB-BP-3 (MGB Biopharma Ltd.)
Nafithromycin (WCK 4873) (Wockhardt Ltd.)
TD-1607 (Theravance Biopharma Inc.)
WCK 771/ WCK 2349 (levonadifloxacin, alalevonadifloxacin) (Wockhardt Ltd.)
Inactive
ACHN-975 (Achaogen Inc.)
EDP-788 (Enanta Pharmaceuticals Inc.)
Phase 2
Active
Afabicin (Debio 1450) (Debiopharm International SA)
Avarofloxacin (Allergan PLC (formerly Actavis PLC))
Brilacidin (Innovation Pharmaceuticals Inc.)
Fetroja (cefiderocol) (Shionogi & Co. Ltd.)
Ceftaroline + avibactam (AstraZeneca PLC/ Forest Laboratories Inc.)
CG-549 (CrystalGenomics Inc.)
Finafloxacin (MerLion Pharmaceuticals GmbH)
Gepotidacin (GSK2140944) (GlaxoSmithKline PLC)
Contezolid (MRX-I) & contezolid acefosamil (MRX-4) (MicuRx Pharmaceuticals Inc.)
Murepavadin (POL7080) (Polyphor AG)
Taigexyn (nemonoxacin) (TaiGen Biotechnology Co. Ltd.)
Radezolid (Melinta Therapeutics Inc.)
Ramoplanin (Nanotherapeutics Inc.)
Ridinilazole (Summit Therapeutics PLC)
Zabofloxacin (Dong Wha Pharmaceutical Co. Ltd.)
Zoliflodacin (ETX0914) (Entasis Therapeutics Inc.)
Inactive
Cefilavacin (R-Pharm)
GSK-1322322 (GlaxoSmithKline PLC)
LFF571 (Novartis AG)
Phase 3
Active
Baxdela (delafloxacin) (Melinta Therapeutics Inc.)
Cadazolid (Actelion Pharmaceuticals Ltd.)
Xerava (eravacycline) (Tetraphase Pharmaceuticals Inc.)
Iclaprim (Motif Bio PLC)
Recarbrio (imipenem/ cilastatin + relebactam) (Merck & Co. Inc.)
Xenleta (lefamulin) (Nabriva Therapeutics PLC)
Nuzyra (omadacycline) (Paratek Pharmaceuticals Inc.)
Zemdri (plazomicin) (Achaogen Inc.)
T-4288 (solithromycin) (Toyama Chemical Co. Ltd.)
Surotomycin (Merck & Co. Inc. (formerly Cubist Pharmaceuticals Inc.))
ARV-1801 (fusidic acid) (Arrevus Inc.)
Vabomere (meropenem + vaborbactam) (The Medicines Company)
Inactive
Ceftobiprole (Basilea Pharmaceutica Ltd.)
New drug application
Active
Inactive
Approved
Active
Avycaz (ceftazidime + avibactam) (AstraZeneca PLC/ Actavis PLC)
Dalvance (dalbavancin) (Durata Therapeutics Inc.)
Orbactiv (oritavancin) (The Medicines Company)
Sivextro (tedizolid) (Cubist Pharmaceuticals Inc.)
Zerbaxa (ceftolozane + tazobactam) (Cubist Pharmaceuticals Inc.)
Inactive
2016
Phase 1
Active
WCK 5222 (cefepime + zidebactam) (Wockhardt Ltd.)
CRS3123 (Crestone Inc.)
Delpazolid (LCB01-0371) (LegoChem Biosciences Inc. (Shanghai HaiHe Pharmaceutical Co., Ltd./ CSPC Pharmaceutical Group Ltd. licensees))
GSK-3342830 (GlaxoSmithKline PLC (Shionogi licensee))
KBP-7072 (KBP BioSciences Pharmaceutical Technical Co. Ltd.)
DNV3837/ DNV3681 (Deinove SA)
Meropenem + nacubactam (OP0595/ RG6080) (Meiji Seika Pharma Co. Ltd./ Fedora Pharmaceuticals Inc.)
MGB-BP-3 (MGB Biopharma Ltd.)
Nafithromycin (WCK 4873) (Wockhardt Ltd.)
TD-1607 (Theravance Biopharma Inc.)
TP-271 (Tetraphase Pharmaceuticals Inc.)
TP-6076 (Tetraphase Pharmaceuticals Inc.)
WCK 771/ WCK 2349 (levonadifloxacin, alalevonadifloxacin) (Wockhardt Ltd.)
Inactive
ACHN-975 (Achaogen Inc.)
BAL30072 (Basilea Pharmaceutica Ltd.)
EDP-788 (Enanta Pharmaceuticals Inc.)
Phase 2
Active
Afabicin (Debio 1450) (Debiopharm International SA)
Brilacidin (Innovation Pharmaceuticals Inc.)
Ceftaroline + avibactam (AstraZeneca PLC/ Forest Laboratories Inc.)
CG-549 (CrystalGenomics Inc.)
Finafloxacin (MerLion Pharmaceuticals GmbH)
Gepotidacin (GSK2140944) (GlaxoSmithKline PLC)
Contezolid (MRX-I) & contezolid acefosamil (MRX-4) (MicuRx Pharmaceuticals Inc.)
Murepavadin (POL7080) (Polyphor AG)
Taigexyn (nemonoxacin) (TaiGen Biotechnology Co. Ltd.)
Ramoplanin (Nanotherapeutics Inc.)
Ridinilazole (Summit Therapeutics PLC)
Zoliflodacin (ETX0914) (Entasis Therapeutics Inc.)
Inactive
Avarofloxacin (Allergan PLC (formerly Actavis PLC))
Cefilavacin (R-Pharm)
GSK-1322322 (GlaxoSmithKline PLC)
LFF571 (Novartis AG)
Radezolid (Melinta Therapeutics Inc.)
Phase 3
Active
Cadazolid (Actelion Pharmaceuticals Ltd.)
Fetroja (cefiderocol) (Shionogi & Co. Ltd.)
Xerava (eravacycline) (Tetraphase Pharmaceuticals Inc.)
Iclaprim (Motif Bio PLC)
Recarbrio (imipenem/ cilastatin + relebactam) (Merck & Co. Inc.)
Xenleta (lefamulin) (Nabriva Therapeutics PLC)
Nuzyra (omadacycline) (Paratek Pharmaceuticals Inc.)
Zemdri (plazomicin) (Achaogen Inc.)
ARV-1801 (fusidic acid) (Arrevus Inc.)
Vabomere (meropenem + vaborbactam) (The Medicines Company)
Zabofloxacin (Dong Wha Pharmaceutical Co. Ltd.)
Inactive
Ceftobiprole (Basilea Pharmaceutica Ltd.)
Surotomycin (Merck & Co. Inc. (formerly Cubist Pharmaceuticals Inc.))
New drug application
Active
Baxdela (delafloxacin) (Melinta Therapeutics Inc.)
T-4288 (solithromycin) (Toyama Chemical Co. Ltd.)
Inactive
Approved
Active
Avycaz (ceftazidime + avibactam) (AstraZeneca PLC/ Actavis PLC)
Dalvance (dalbavancin) (Durata Therapeutics Inc.)
Orbactiv (oritavancin) (The Medicines Company)
Sivextro (tedizolid) (Cubist Pharmaceuticals Inc.)
Zerbaxa (ceftolozane + tazobactam) (Cubist Pharmaceuticals Inc.)
Inactive
2017
Phase 1
Active
AIC499 (AiCuris Anti-infective Cures GmbH)
Cefepime + taniborbactam (VNRX-5133) (Venatorx Pharmaceuticals Inc.)
WCK 5222 (cefepime + zidebactam) (Wockhardt Ltd.)
CRS3123 (Crestone Inc.)
Delpazolid (LCB01-0371) (LegoChem Biosciences Inc. (Shanghai HaiHe Pharmaceutical Co., Ltd./ CSPC Pharmaceutical Group Ltd. licensees))
DS-2969 (Daiichi Sankyo Co., Ltd.)
Sulbactam + durlobactam (Entasis Therapeutics Inc.)
GSK-3342830 (GlaxoSmithKline PLC (Shionogi licensee))
KBP-7072 (KBP BioSciences Pharmaceutical Technical Co. Ltd.)
DNV3837/ DNV3681 (Deinove SA)
Meropenem + nacubactam (OP0595/ RG6080) (Meiji Seika Pharma Co. Ltd./ Fedora Pharmaceuticals Inc.)
MGB-BP-3 (MGB Biopharma Ltd.)
SPR741 (Spero Therapeutics Inc.)
Tebipenem/ tebipenem pivoxil hydrobromide (Spero Therapeutics Inc.)
TP-271 (Tetraphase Pharmaceuticals Inc.)
TP-6076 (Tetraphase Pharmaceuticals Inc.)
Inactive
ACHN-975 (Achaogen Inc.)
BAL30072 (Basilea Pharmaceutica Ltd.)
EDP-788 (Enanta Pharmaceuticals Inc.)
TD-1607 (Theravance Biopharma Inc.)
Phase 2
Active
Afabicin (Debio 1450) (Debiopharm International SA)
BOS-228 (Boston Pharmaceuticals Inc.)
Brilacidin (Innovation Pharmaceuticals Inc.)
Cefepime + enmetazobactam (Allecra Therapeutics GmbH)
CG-549 (CrystalGenomics Inc.)
Finafloxacin (MerLion Pharmaceuticals GmbH)
Gepotidacin (GSK2140944) (GlaxoSmithKline PLC)
Murepavadin (POL7080) (Polyphor AG)
Nafithromycin (WCK 4873) (Wockhardt Ltd.)
Taigexyn (nemonoxacin) (TaiGen Biotechnology Co. Ltd.)
OPS-2071 (Otsuka Pharmaceutical Co. Ltd.)
Ridinilazole (Summit Therapeutics PLC)
WCK 771/ WCK 2349 (levonadifloxacin, alalevonadifloxacin) (Wockhardt Ltd.)
Zoliflodacin (ETX0914) (Entasis Therapeutics Inc.)
Inactive
Avarofloxacin (Allergan PLC (formerly Actavis PLC))
Ceftaroline + avibactam (AstraZeneca PLC/ Forest Laboratories Inc.)
GSK-1322322 (GlaxoSmithKline PLC)
LFF571 (Novartis AG)
Radezolid (Melinta Therapeutics Inc.)
Ramoplanin (Nanotherapeutics Inc.)
Phase 3
Active
Cadazolid (Actelion Pharmaceuticals Ltd.)
Fetroja (cefiderocol) (Shionogi & Co. Ltd.)
Cefilavacin (R-Pharm)
Ceftobiprole (Basilea Pharmaceutica Ltd.)
Xerava (eravacycline) (Tetraphase Pharmaceuticals Inc.)
Iclaprim (Motif Bio PLC)
Recarbrio (imipenem/ cilastatin + relebactam) (Merck & Co. Inc.)
Lasvic (lascufloxacin) (Kyorin Pharmaceutical Co. Ltd.)
Xenleta (lefamulin) (Nabriva Therapeutics PLC)
Contezolid (MRX-I) & contezolid acefosamil (MRX-4) (MicuRx Pharmaceuticals Inc.)
Nuzyra (omadacycline) (Paratek Pharmaceuticals Inc.)
T-4288 (solithromycin) (Toyama Chemical Co. Ltd.)
Sulopenem/ sulopenem- etzadroxil- probenecid (Iterum Therapeutics PLC)
ARV-1801 (fusidic acid) (Arrevus Inc.)
Zabofloxacin (Dong Wha Pharmaceutical Co. Ltd.)
Inactive
Surotomycin (Merck & Co. Inc. (formerly Cubist Pharmaceuticals Inc.))
New drug application
Active
Zemdri (plazomicin) (Achaogen Inc.)
Inactive
Approved
Active
Avycaz (ceftazidime + avibactam) (AstraZeneca PLC/ Actavis PLC)
Baxdela (delafloxacin) (Melinta Therapeutics Inc.)
Dalvance (dalbavancin) (Durata Therapeutics Inc.)
Orbactiv (oritavancin) (The Medicines Company)
Sivextro (tedizolid) (Cubist Pharmaceuticals Inc.)
Vabomere (meropenem + vaborbactam) (The Medicines Company)
Zerbaxa (ceftolozane + tazobactam) (Cubist Pharmaceuticals Inc.)
Inactive
2018
Phase 1
Active
Ibezapolstat (ACX-362E) (Acurx Pharmaceuticals LLC)
AIC499 (AiCuris Anti-infective Cures GmbH)
Cefepime + taniborbactam (VNRX-5133) (Venatorx Pharmaceuticals Inc.)
WCK 5222 (cefepime + zidebactam) (Wockhardt Ltd.)
CRS3123 (Crestone Inc.)
Delpazolid (LCB01-0371) (LegoChem Biosciences Inc. (Shanghai HaiHe Pharmaceutical Co., Ltd./ CSPC Pharmaceutical Group Ltd. licensees))
ETX0282CPDP/ ETX1317 (Entasis Therapeutics Inc.)
KBP-7072 (KBP BioSciences Pharmaceutical Technical Co. Ltd.)
DNV3837/ DNV3681 (Deinove SA)
Meropenem + nacubactam (OP0595/ RG6080) (Meiji Seika Pharma Co. Ltd./ Fedora Pharmaceuticals Inc.)
MGB-BP-3 (MGB Biopharma Ltd.)
SPR206 (Spero Therapeutics Inc.)
SPR741 (Spero Therapeutics Inc.)
TP-271 (Tetraphase Pharmaceuticals Inc.)
TP-6076 (Tetraphase Pharmaceuticals Inc.)
Inactive
ACHN-975 (Achaogen Inc.)
BAL30072 (Basilea Pharmaceutica Ltd.)
DS-2969 (Daiichi Sankyo Co., Ltd.)
EDP-788 (Enanta Pharmaceuticals Inc.)
GSK-3342830 (GlaxoSmithKline PLC (Shionogi licensee))
TD-1607 (Theravance Biopharma Inc.)
Phase 2
Active
Afabicin (Debio 1450) (Debiopharm International SA)
BOS-228 (Boston Pharmaceuticals Inc.)
Brilacidin (Innovation Pharmaceuticals Inc.)
CG-549 (CrystalGenomics Inc.)
Sulbactam + durlobactam (Entasis Therapeutics Inc.)
Finafloxacin (MerLion Pharmaceuticals GmbH)
Gepotidacin (GSK2140944) (GlaxoSmithKline PLC)
Nafithromycin (WCK 4873) (Wockhardt Ltd.)
Taigexyn (nemonoxacin) (TaiGen Biotechnology Co. Ltd.)
OPS-2071 (Otsuka Pharmaceutical Co. Ltd.)
Zoliflodacin (ETX0914) (Entasis Therapeutics Inc.)
Inactive
Avarofloxacin (Allergan PLC (formerly Actavis PLC))
Ceftaroline + avibactam (AstraZeneca PLC/ Forest Laboratories Inc.)
GSK-1322322 (GlaxoSmithKline PLC)
LFF571 (Novartis AG)
Radezolid (Melinta Therapeutics Inc.)
Ramoplanin (Nanotherapeutics Inc.)
Phase 3
Active
Cefepime + enmetazobactam (Allecra Therapeutics GmbH)
Fetroja (cefiderocol) (Shionogi & Co. Ltd.)
Cefilavacin (R-Pharm)
Ceftobiprole (Basilea Pharmaceutica Ltd.)
Recarbrio (imipenem/ cilastatin + relebactam) (Merck & Co. Inc.)
Contezolid (MRX-I) & contezolid acefosamil (MRX-4) (MicuRx Pharmaceuticals Inc.)
Murepavadin (POL7080) (Polyphor AG)
Ridinilazole (Summit Therapeutics PLC)
T-4288 (solithromycin) (Toyama Chemical Co. Ltd.)
Tebipenem/ tebipenem pivoxil hydrobromide (Spero Therapeutics Inc.)
Sulopenem/ sulopenem- etzadroxil- probenecid (Iterum Therapeutics PLC)
ARV-1801 (fusidic acid) (Arrevus Inc.)
WCK 771/ WCK 2349 (levonadifloxacin, alalevonadifloxacin) (Wockhardt Ltd.)
Inactive
Cadazolid (Actelion Pharmaceuticals Ltd.)
Surotomycin (Merck & Co. Inc. (formerly Cubist Pharmaceuticals Inc.))
Zabofloxacin (Dong Wha Pharmaceutical Co. Ltd.)
New drug application
Active
Iclaprim (Motif Bio PLC)
Lasvic (lascufloxacin) (Kyorin Pharmaceutical Co. Ltd.)
Xenleta (lefamulin) (Nabriva Therapeutics PLC)
Inactive
Approved
Active
Avycaz (ceftazidime + avibactam) (AstraZeneca PLC/ Actavis PLC)
Baxdela (delafloxacin) (Melinta Therapeutics Inc.)
Dalvance (dalbavancin) (Durata Therapeutics Inc.)
Xerava (eravacycline) (Tetraphase Pharmaceuticals Inc.)
Nuzyra (omadacycline) (Paratek Pharmaceuticals Inc.)
Orbactiv (oritavancin) (The Medicines Company)
Zemdri (plazomicin) (Achaogen Inc.)
Sivextro (tedizolid) (Cubist Pharmaceuticals Inc.)
Vabomere (meropenem + vaborbactam) (The Medicines Company)
Zerbaxa (ceftolozane + tazobactam) (Cubist Pharmaceuticals Inc.)
Inactive
2019
Phase 1
Active
Ibezapolstat (ACX-362E) (Acurx Pharmaceuticals LLC)
WCK 5222 (cefepime + zidebactam) (Wockhardt Ltd.)
CRS3123 (Crestone Inc.)
Delpazolid (LCB01-0371) (LegoChem Biosciences Inc. (Shanghai HaiHe Pharmaceutical Co., Ltd./ CSPC Pharmaceutical Group Ltd. licensees))
ETX0282CPDP/ ETX1317 (Entasis Therapeutics Inc.)
KBP-7072 (KBP BioSciences Pharmaceutical Technical Co. Ltd.)
Meropenem + nacubactam (OP0595/ RG6080) (Meiji Seika Pharma Co. Ltd./ Fedora Pharmaceuticals Inc.)
SPR206 (Spero Therapeutics Inc.)
SPR741 (Spero Therapeutics Inc.)
TP-271 (Tetraphase Pharmaceuticals Inc.)
TP-6076 (Tetraphase Pharmaceuticals Inc.)
Apramycin (Juvabis AG)
Oravance (QPX-2015 + QPX-7728) (Qpex Biopharma/ Brii Biosciences)
TXA709/ TXA707 (Taxis Pharmaceuticals Inc.)
VNRX-7145 + ceftibuten (Venatorx Pharmaceuticals Inc.)
Inactive
ACHN-975 (Achaogen Inc.)
AIC499 (AiCuris Anti-infective Cures GmbH)
BAL30072 (Basilea Pharmaceutica Ltd.)
DS-2969 (Daiichi Sankyo Co., Ltd.)
EDP-788 (Enanta Pharmaceuticals Inc.)
GSK-3342830 (GlaxoSmithKline PLC (Shionogi licensee))
TD-1607 (Theravance Biopharma Inc.)
Phase 2
Active
Afabicin (Debio 1450) (Debiopharm International SA)
BOS-228 (Boston Pharmaceuticals Inc.)
Brilacidin (Innovation Pharmaceuticals Inc.)
CG-549 (CrystalGenomics Inc.)
Finafloxacin (MerLion Pharmaceuticals GmbH)
DNV3837/ DNV3681 (Deinove SA)
MGB-BP-3 (MGB Biopharma Ltd.)
Nafithromycin (WCK 4873) (Wockhardt Ltd.)
Taigexyn (nemonoxacin) (TaiGen Biotechnology Co. Ltd.)
ARV-1801 (fusidic acid) (Arrevus Inc.)
Benapenem (Sihuan Pharmaceutical Co. Ltd.)
TNP-2092 (TenNor Therapeutics Ltd.)
Inactive
Avarofloxacin (Allergan PLC (formerly Actavis PLC))
Ceftaroline + avibactam (AstraZeneca PLC/ Forest Laboratories Inc.)
GSK-1322322 (GlaxoSmithKline PLC)
LFF571 (Novartis AG)
OPS-2071 (Otsuka Pharmaceutical Co. Ltd.)
Radezolid (Melinta Therapeutics Inc.)
Ramoplanin (Nanotherapeutics Inc.)
Phase 3
Active
Cefepime + enmetazobactam (Allecra Therapeutics GmbH)
Cefepime + taniborbactam (VNRX-5133) (Venatorx Pharmaceuticals Inc.)
Cefilavacin (R-Pharm)
Ceftobiprole (Basilea Pharmaceutica Ltd.)
Sulbactam + durlobactam (Entasis Therapeutics Inc.)
Gepotidacin (GSK2140944) (GlaxoSmithKline PLC)
Iclaprim (Motif Bio PLC)
Contezolid (MRX-I) & contezolid acefosamil (MRX-4) (MicuRx Pharmaceuticals Inc.)
Ridinilazole (Summit Therapeutics PLC)
T-4288 (solithromycin) (Toyama Chemical Co. Ltd.)
Tebipenem/ tebipenem pivoxil hydrobromide (Spero Therapeutics Inc.)
Sulopenem/ sulopenem- etzadroxil- probenecid (Iterum Therapeutics PLC)
Zoliflodacin (ETX0914) (Entasis Therapeutics Inc.)
Inactive
Cadazolid (Actelion Pharmaceuticals Ltd.)
Murepavadin (POL7080) (Polyphor AG)
Surotomycin (Merck & Co. Inc. (formerly Cubist Pharmaceuticals Inc.))
Zabofloxacin (Dong Wha Pharmaceutical Co. Ltd.)
New drug application
Active
WCK 771/ WCK 2349 (levonadifloxacin, alalevonadifloxacin) (Wockhardt Ltd.)
Inactive
Approved
Active
Avycaz (ceftazidime + avibactam) (AstraZeneca PLC/ Actavis PLC)
Baxdela (delafloxacin) (Melinta Therapeutics Inc.)
Fetroja (cefiderocol) (Shionogi & Co. Ltd.)
Dalvance (dalbavancin) (Durata Therapeutics Inc.)
Xerava (eravacycline) (Tetraphase Pharmaceuticals Inc.)
Recarbrio (imipenem/ cilastatin + relebactam) (Merck & Co. Inc.)
Lasvic (lascufloxacin) (Kyorin Pharmaceutical Co. Ltd.)
Xenleta (lefamulin) (Nabriva Therapeutics PLC)
Nuzyra (omadacycline) (Paratek Pharmaceuticals Inc.)
Orbactiv (oritavancin) (The Medicines Company)
Zemdri (plazomicin) (Achaogen Inc.)
Sivextro (tedizolid) (Cubist Pharmaceuticals Inc.)
Vabomere (meropenem + vaborbactam) (The Medicines Company)
Zerbaxa (ceftolozane + tazobactam) (Cubist Pharmaceuticals Inc.)
Inactive
Notes: Candidates included in this data visualization are consistent with Pew’s methodology for tracking antibiotics in clinical development. The analysis captures the status of antibiotics in the pipeline beginning in 2014, including those approved by the FDA and other regulatory agencies that year. More information about methodology and the full underlying data can be found in Pew’s latest pipeline analysis . This interactive tool is updated annually.